Research progress on the mechanism of podocyte injury mediated by NLRP3 inflammasome

doi:10.3877/cma.j.issn.2095-3216.2020.06.006

Abstract

Abstract:

Podocyte injury is one of the main pathological bases of renal-derived proteinuria, and occupies an important position in the occurrence, progression, and prognosis of renal diseases. In recent years, Nod-like receptor protein 3 (NLRP3) inflammasome-mediated podocyte injury has become a research hotspot. NLRP3 inflammasome can be activated by multiple pathways, which in turn activates caspase-1, promotes the maturation and secretion of inflammatory factors IL-1β and IL-18, and changes the expression levels of related specific proteins, ultimately leading to podocyte injury, glomerulosclerosis, and end-stage renal disease. This article reviewed the research on activation pathways and signal pathways of NLRP3 inflammasome in podocyte injury in recent years, with a view to providing new targets for the prevention and treatment of podocyte injury-related renal diseases.

Key words: Podocyte injury, NLRP3 inflammasome, Reactive oxygen species, Therapy

Jingyi Sun, Xuyan Liu, Wei Jiang. Research progress on the mechanism of podocyte injury mediated by NLRP3 inflammasome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(06): 267-271.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.06.006

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I06/267

Figures/Tables 2

References 38

[1]	Ma RX, Liu LQ, Jiang W, et al. FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression [J]. Int J Clin Exp Pathol, 2015, 8(11): 14063-14074.
[2]	王彤，马瑞霞，武国华，等. 他克莫司通过上调自噬作用保护2型糖尿病大鼠足细胞[J]. 中华肾脏病杂志，2016, 32(3): 195-199.
[3]	Ma R, Jiang W, Li Z, et al. Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients [J]. Lupus, 2016, 25(14): 1577-1586.
[4]	Zhang C, Boini KM, Xia M, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia [J]. Hypertension, 2012, 60(1): 154-162.
[5]	Wang W, Ding XQ, Gu TT, et al. Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377 [J]. Free Radical Bio Med, 2015, 83: 214-226.
[6]	Singh GB, Kshirasagar N, Patibandla S, et al. Nicotine instigates podocyte injury via NLRP3 inflammasomes activation [J]. Aging (Albany NY), 2019, 11(24): 12810-12821.
[7]	Haque S, Lan XQ, Wen HX, et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy [J]. Am J Pathol, 2016, 186(2): 347-358.
[8]	Boini KM, Xia M, Koka S, et al. Instigation of NLRP3 inflammasome activation and glomerular injury in mice on the high fat diet: role of acid sphingomyelinase gene [J]. Oncotarget, 2016, 7(14): 19031-19044.
[9]	Abais JM, Zhang C, Xia M, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia [J]. Antioxid Redox Sing, 2013, 18(13): 1537-1548.
[10]	Conley SM, Abais-Battad JM, Yuan XX, et al. Contribution of guanine nucleotide exchange factor Vav2 to NLRP3 inflammasome activation in mouse podocytes during hyperhomocysteinemia [J]. Free Radical Bio Med, 2017, 106: 236-244.
[11]	Abais JM, Xia M, Li G, et al. Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia [J]. Free Radical Bio Med, 2014, 67: 211-220.
[12]	Abais JM, Xia M, Li G, et al. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin-interacting protein (TXNIP) during hyperhomocysteinemia [J]. J Biol Chem, 2014, 289(39): 27159-27168.
[13]	Gao P, Meng X, Su H, et al. Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy [J]. Biochim Biophys Acta, 2014, 1843(11): 2448-2460.
[14]	Hong JN, Li GB, Zhang QH, et al. D-ribose induces podocyte NLRP3 in ammasome activation and glomerular injury via AGEs/RAGE pathway [J]. Front Cell Dev Biol, 2019, 10(30): 849-860.
[15]	Yeh WJ, Yang HY, Pai MH, et al. Long-term administration of advanced glycation end product stimulates the activation of NLRP3 inflammasome and sparking the development of renal injury [J]. J Nutr Biochem, 2017, 39: 68-76.
[16]	Yan J, Li Y, Yang H, et al. Interleukin-17A participates in podocyte injury by inducing IL-1β secretion through ROS-NLRP3 inflammasome-caspase-1 pathway [J]. Scand J Immunol, 2018, 87(4): e12645.
[17]	Zhao M, Bai M, Ding GX, et al. Angiotensin II stimulates the NLRP3 inflammasome to induce podocyte injury and mitochondrial dysfunction [J]. Kidney Dis (Basel), 2018, 4(2): 83-94.
[18]	Fu R, Guo C, Wang S, et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis [J]. Arthritis Rheumatol, 2017, 69(8): 1636-1646.
[19]	Singh GB, Kshirasagar N, Patibandla S, et al. Nicotine instigates podocyte injury via NLRP3 inflammasomes activation [J]. Aging (Albany NY), 2019, 11(24): 12810-12821.
[20]	Mi B, Ying C, Min Z, et al. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury [J]. Am J Physiol Renal Physiol, 2017, 312(4): F556-F564.
[21]	Hou XX, Dong HR, Sun LJ, et al. Purinergic 2X7 receptor is involved in the podocyte damage of obesity-related glomerulopathy via activating nucleotide-binding and oligomerization domain-like receptor protein 3 inflammasome [J]. Chin Med J (Engl), 2018, 131(22): 2713-2725.
[22]	Wang C, Hou XX, Rui HL, et al. Artificially cultivated Ophiocordyceps sinensis alleviates diabetic nephropathy and its podocyte injury via inhibiting P2X7R expression and NLRP3 inflammasome activation [J]. J Diabetes Res, 2018, 2018: 1390418.
[23]	Yang XJ, Wu Y, Li QQ, et al. CD36 promotes podocyte apoptosis by activating the pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome [J]. Med Sci Monitor, 2018, 24: 6832-6839.
[24]	Kagan JC, Horng T. NLRP3 inflammasome activation: CD36 serves double duty [J]. Nat Immunol, 2013, 14(8): 772-774.
[25]	Zhao J, Rui HL, Yang M, et al. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy [J]. Media Inflamm, 2019, 2019: 3172647.
[26]	Boini KM, Xia M, Abais JM, et al. Activation of inflammasomes in podocyte injury of mice on the high fat diet: effects of ASC gene deletion and silencing [J]. Biochim Biophys Acta, 2014, 1843(5): 836-845.
[27]	Liu B, Lu R, Li H, et al. Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome [J]. Phytomedicine, 2019, 59: 152913.
[28]	Yi H, Peng R, Zhang LY, et al. LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy [J]. Cell Death Dis, 2017, 8(2): e2583.
[29]	Ma CH, Kang LL, Ren HM, et al. Simiao pill ameliorates renal glomerular injury via increasing Sirt1 expression and suppressing NF-κB/NLRP3 inflammasome activation in high fructose-fed rats [J]. J Ethnopharmacol, 2015, 172: 108-117.
[30]	Hua KF, Yang SM, Kao TY, et al. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-κB/NLRP3 pathway [J]. PLoS One, 2013, 8(10): e77794.
[31]	Chen L, Lan Z. Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-κB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway [J]. Food Funct, 2017, 8(5): 1785-1792.
[32]	Yang SM, Ka SM, Wu HL, et al. Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis [J]. Diabetologia, 2014, 57(2): 424-434.
[33]	Guo CH, Fu R, Zhou MJ, et al. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation [J]. J Autoimmun, 2019, 103: 102286.
[34]	Peng W, Pei GQ, Tang Y, et al. IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy [J]. J Transl Med, 2019, 17(1): 406.
[35]	Li G, Chen Z, Bhat OM, et al. NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury [J]. J Lipid Res, 2017, 58(6): 1080-1090.
[36]	Li G, Xia M, Abais J, et al. Protective action of anandamide and its COX-2 metabolite against L-homocysteine-induced NLRP3 inflammasome activation and injury in podocytes [J]. J Pharmacol Exp Ther, 2016, 358(1): 61-70.
[37]	Shahzad K, Bock F, Aldabet MM, et al. Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy [J]. Sci Rep, 2016, 6: 34228.
[38]	Ren Y, Wang D, Lu F, et al. Coptidis Rhizoma inhibits NLRP3 inflammasome activation and alleviates renal damage in early obesity-related glomerulopathy [J]. Phytomedicine, 2018, 49: 52-65.

Please choose a citation manager

Content to export